+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Radiopharmaceuticals - Global Market Trajectory & Analytics

  • ID: 835008
  • Report
  • July 2020
  • Region: Global
  • 400 Pages
  • Global Industry Analysts, Inc
New Therapeutic Radiopharmaceuticals to Drive Global Market
Global Radiopharmaceuticals Market to Reach $9.7 Billion by 2027

Amid the COVID-19 crisis, the global market for Radiopharmaceuticals estimated at US$5.9 Billion in the year 2020, is projected to reach a revised size of US$9.7 Billion by 2027, growing at a CAGR of 7.3% over the analysis period 2020-2027. SPECT Radioisotopes, one of the segments analyzed in the report, is projected to record a 7.3% CAGR and reach US$4.3 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the PET Radioisotopes segment is readjusted to a revised 7.7% CAGR for the next 7-year period.

The U.S. Market is Estimated at $1.6 Billion, While China is Forecast to Grow at 11.1% CAGR

The Radiopharmaceuticals market in the U.S. is estimated at US$1.6 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.1 Billion by the year 2027 trailing a CAGR of 11% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.9% and 6.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.7% CAGR.

Beta Emitters Segment to Record 8.9% CAGR

In the global Beta Emitters segment, USA, Canada, Japan, China and Europe will drive the 8.3% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$677.9 Million in the year 2020 will reach a projected size of US$1.2 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1.3 Billion by the year 2027, while Latin America will expand at a 10.4% CAGR through the analysis period. We bring years of research experience to this 17th edition of our report. The 400-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.

Competitors identified in this market include, among others:
  • Actinium Pharmaceuticals Inc.
  • Alliance Medical
  • Alseres Pharmaceuticals Inc.
  • Avid Radiopharmaceuticals
  • Bayer HealthCare, Radiology Division
  • Bracco Diagnostics Inc.
  • Cardinal Health, Inc.
  • GE Healthcare
  • Immunomedics, Inc.
  • Ion Beam Applications SA
  • Jubilant Pharma
  • Lantheus Medical Imaging Inc.
  • Medi-Radiopharma Ltd.
  • Nordion, Inc.
  • Peregrine Pharmaceuticals, Inc.
  • PETNET Solutions Inc.
  • Positron Corporation
  • Triad Isotopes Inc.

The global analysis and forecast periods covered within the report are 2020-2027 (Current & Future Analysis) and 2012-2019 (Historic Review). Research estimates are provided for 2020, while research projections cover the period 2021-2027.
Note: Product cover images may vary from those shown

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Impact of Covid-19 and a Looming Global Recession

A Prelude

Recent Market Activity

Current & Future Analysis

Diagnostic Radiopharmaceuticals: The Dominant Segment

Select Cardiology and Oncology Radiopharmaceuticals

New Therapeutic Radiopharmaceuticals to Drive Global Market

Competition

Relevant Aspects of Radiopharmaceutical Production

Intra-operative Lymphatic Mapping (ILM): Creates New Opportunities for Radiopharmaceuticals in Cancer Detection

Global Competitor Market Shares

Radiopharmaceuticals Competitor Market Share Scenario Worldwide (in %): 2020 & 2029

2. FOCUS ON SELECT PLAYERS

Actinium Pharmaceuticals, Inc. (USA)

Alliance Medical (UK)

Alseres Pharmaceuticals, Inc. (USA)

Avid Radiopharmaceuticals (USA)

Bayer HealthCare Pharmaceuticals (Germany)

Bracco Diagnostics, Inc. (USA)

Cardinal Health, Inc. (USA)

GE Healthcare (UK)

Ion Beam Applications S.A (Belgium)

Immunomedics, Inc. (USA)

Jubilant Pharma (India)

Lantheus Medical Imaging Inc. (USA)

Medi-Radiopharma Ltd (Hungary)

Nordion, Inc. (Canada)

Peregrine Pharmaceuticals, Inc. (USA)

PETNET Solutions Inc. (USA)

Positron Corporation (USA)

Triad Isotopes, Inc. (USA)

3. MARKET TRENDS & DRIVERS

Rise in Incidence of Cancer - A Major Growth Driver

Cancer Prone Sites based on Age

Ageing Population - A Vital Demography

Global CVD Stats

Market Drivers

Growing Acceptance in Cancer Treatment

Increasing Acceptance of Disease-Targeted Treatment

Growing Emphasis of Accurate Diagnosis

Expanding Molecular Imaging Applications

Market Restraints

Stringent Regulatory Guidelines for Manufacture, Storage and Usage

Global Supply Shortages

Price Sensitivity & Competition from Alternatives

Lack of Dosage Standards for Pediatric Patients Limits Radiopharmaceutical Efficacy

Unfounded Fears of Radiation Exposure Hinder Growth

Bottlenecks in Developing Markets

Recognition of Intrinsic Cost Benefits: Critical to Market Acceptance

Increasing Uptake of PET: A Prime Growth Driver

Non-Reactor Based TC-99m Production to Drive SPECT Growth

New Radiopharmaceuticals Drive Adoption of Molecular Imaging

PET and SPECT in Cardiovascular Imaging

Innovative Radiotracers - Key to PET & SPECT Success in Cardiovascular Imaging

Cardiac Amyloidosis Visualization - A Potential Application for PET

Application of PET in Drug Development to Expand Opportunities

Industry Focus Gears up for innovative Radiopharmaceuticals with Therapeutic Benefits

Innovative Radiopharmaceuticals to Boost Cardiac Applications

Personalized Medicine to Drive Nuclear Medicine

Rise in Incidence of Neurological Disorders to Drive Growth

Battling Alzheimer’s Disease - A Powerful Market Force for Nuclear Medicine

Combating the Shortage of RadioIsotopes

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

GEOGRAPHIC MARKET ANALYSIS

UNITED STATES

Market Facts & Figures

US Radiopharmaceuticals Market Share (in %) by Company: 2020 & 2025

Market Analytics

CANADA

JAPAN

CHINA

EUROPE

Market Facts & Figures

European Radiopharmaceuticals Market: Competitor Market Share Scenario (in %) for 2020 & 2025

Market Analytics

FRANCE

GERMANY

ITALY

UNITED KINGDOM

SPAIN

RUSSIA

REST OF EUROPE

ASIA-PACIFIC

AUSTRALIA

INDIA

SOUTH KOREA

REST OF ASIA-PACIFIC

LATIN AMERICA

ARGENTINA

BRAZIL

MEXICO

REST OF LATIN AMERICA

MIDDLE EAST

IRAN

ISRAEL

SAUDI ARABIA

UNITED ARAB EMIRATES

REST OF MIDDLE EAST

AFRICA

IV. COMPETITION

Total Companies Profiled: 61

Note: Product cover images may vary from those shown
Adroll
adroll